Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue

Core Insights - Profusa, Inc. has launched its Healthcare Research version of the Lumee tissue oxygen monitoring system targeting the global CRO market, which is projected to reach $47.9 billion by 2025, growing at a CAGR of 7% [1][3] - The initiative aims to meet the increasing demand for real-time biological data in drug development, allowing CRO partners to integrate the technology into their workflows with minimal implementation risk [2][4] Company Developments - Profusa's Lumee tissue oxygen products are commercially available and ready for immediate deployment, providing continuous, real-time measurement of tissue oxygenation for various research applications [4] - The company has appointed Sean Givens as the Head of Government and Healthcare Research Business to lead commercialization efforts, emphasizing the strong interest in their validated sensors across the industry [5][6] Market Context - The CRO and pharmaceutical services market is experiencing robust growth due to rising R&D investments and regulatory support for new methodologies, with forecasts indicating the market could expand to over $91.2 billion by 2034 [3] - Profusa's technology supports research in critical areas such as wound healing and oncology, where understanding tissue oxygen dynamics is essential for therapeutic responses [4]